Onco Actu du 28 octobre 2019

	3.1.1 PRÉVENTION - TABAC - E-CIGS
Behind The Scenes Of CDC's Vaping Investigation [NPR] Given the scope and the mysterious nature of the illness, the CDC set up an incident command center to coordinate its response. In elevating an issue like this, Schuchat says the CDC has directed about 140 scientists and other staff to step away from their normal work and give their full attention to the crisis.
Some States With Legal Weed Embrace Vaping Bans, Warn Of Black Market Risks [NPR] "There is this risk when you ban something [legal] that people will be driven to the black market," says Ziva Cooper, director of the UCLA Cannabis Research Initiative. Cooper says the regulated cannabis market is already fraught with problems.
USC study implicates flavored e-cigs in teen vaping epidemic [USC] Researchers found that 64% of teens using flavored e-cigs were still vaping six months later, compared to 43% who used more traditional flavors.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Factors linked to poor treatment outcomes in ALL [Baylor College of Medicine] The researchers found an association between central carbon metabolism and minimal residual disease after treatment. Experiments in the laboratory showed that treating ALL cells with drugs that interfere with central carbon metabolism effectively reduced cancer growth, opening the possibility that a similar approach could be translated to clinic in the future.
Margaret McCartney: Cancer screening review diminishes informed choice [BMJ] The UK National Screening Committee is one of the few bits of the NHS which works very well. It stands for evidence, for cool assessment of cost effectiveness and potential harms, and calm consideration. As I have written before, it is deeply boring, and we should be grateful for that. It is light not heat, and science before soundbites. Anything that threatens, rather than strengthens that function is to be resisted.
	4.12 BIOPSIES LIQUIDES
German university finds ‘severe’ misconduct by researcher who promoted questionable cancer blood test [Science] The promotion of the test “is totally unacceptable,” says Gerd Gigerenzer, director of the Harding Center for Risk Literacy at the Max Planck Institute for Human Development in Berlin, who has followed the case. “Trying to market such a test … is close to a crime.”
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
Bull’s-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place [Memorial Sloan Kettering Cancer Center] In the Cancer Cell paper, the investigators report the development of a precision medicine tactic that uses a PET tracer with radioactive iodine.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Treatment Targets Identified by RNA Sequencing in Pediatric Cancer Cases [Genome Web] "Our work suggests that direct investigations of the clinical utility and effectiveness of tumor RNA-seq-derived gene expression information will be valuable, and the next phase of our project will focus on defining the incremental benefit of this approach."
Pediatric cancer study shows usefulness of gene expression analysis [UC Santa Cruz] The study, published October 25 in JAMA Network Open, looked at 144 tumor samples from 128 pediatric cancer patients enrolled in four precision medicine clinical studies in the United States and Canada.
Direct-to-consumer genetic test results may be unreliable [Reuters] “DTC tests may fulfill an individual’s curiosity about ancestry,” she told Reuters Health by email. “However, they are not powerful enough to replace standard care at the present time, particularly in individuals with increased genetic disease risk.”
	4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
UK Regulator Has “Competition Concerns” Over Illumina-PacBio Tie-Up [Xconomy] Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition in the region and reduce industry innovation.
	4.9 DÉP., DIAG. & PRONO. - SEIN
A tourist finds breast cancer after a thermal scan at Camera Obscura. That doesn’t mean thermography works. [Respectful Insolence] It is almost certain that her detection of her breast cancer was not because the Camera Obscura thermal image detected her cancer but because a happy accident that, for whatever reason, that patch of skin (or even her clothings) over her breast was a little hotter than the surrounding skin and clothing, which led her to wonder and to go to see her doctor. She’s a very lucky woman.
	5. TRAITEMENTS
Jeffrey Aronson: When I Use a Word . . . Drug shortages—harms and errors [BMJ] In surveying the literature, I was struck by how infrequently clinical harms attributed to drug shortages had been reported until relatively recently.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Gilead CAR-T sales slow, renewing growth doubts [Biopharma Dive] Sales of Gilead's flagship cell therapy Yescarta totaled $118 million from July to September, slightly less than what the biotech recorded in the second quarter and below Wall Street expectations.
Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma [NCI] The patients—part of a small “run in” group used to evaluate the impact of gamma-secretase inhibitors (GSIs) independently from the CAR T-cell therapy—received three doses of a GSI over 5 days. The treatment nearly tripled the percentage of myeloma cells with measurable expression of BCMA and increased expression in myeloma cells by a median of 33-fold.
Behind the Scenes of a Radical New Cancer Cure [Undark] I’ve now treated several patients with the new cancer gene therapy called CAR-T, but there’s still a lot to learn.
	5.2.1 PHARMA - PARTENARIATS
Novartis sends second wagon after KRAS gold rush [EndPoints] This new collaboration will see Novartis dig its hands directly into RAS inhibitors as it works to turn the Beatson’s molecules into actionable therapies.
	5.2.6 PHARMA - BIOTECH
Syros links SY-1425 combo to 50%-plus AML complete response rate [Fierce Biotech] Seven of the 13 newly diagnosed AML patients with a certain biomarker had full complete responses after receiving the RARα agonist in combination with Celgene’s Vidaza.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
European Commission Approves Astellas’ XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation [Astellas] Approval follows accelerated assessment, orphan designation by European Medicines Agency.
	5.9 AACR
CDK4/6 Inhibitors Effective in Mice Bearing Multiple Human Cancer Types [NCI] “Based on our results, we believe that CDK inhibition may be a viable therapeutic option in a host of different cancer types, especially in combination with existing therapies.”
AG-270 is Safe and Shows Signs of Activity in Patients with Cancers Lacking the MTAP Gene [AACR] As of mid-August 2019, Heist and colleagues had enrolled in the trial 39 patients who had an advanced solid tumor with MTAP deletion (or CDKN2A loss, which usually correlates with MTAP deletion).
Bispecific Antibody MCLA-128 Shows Clinical Activity in Patients With Solid Tumors Harboring NRG1 Gene Fusions [AACR] Schram and the MSK team performed next-generation sequencing of solid tumors from patients and identified 29 patients whose tumors (pancreatic, lung, breast, prostate, and gallbladder cancer, and sarcoma and lymphoma, among others) were positive for NRG1 fusions. Of these patients, three were treated with 750 mg MCLA-128 intravenously every other week, and all three had significant tumor shrinkage.
	6.2 IMPLANTS MAMMAIRES
Allergan backs mobile app for breast implant info exchange between patients and plastic surgeons [Fierce Pharma] Patients will be able to download the app, expected for release in 2020, but Allergan will also promote the Patient App on its Natrelle breast implant digital and social media channels as well as in in-office brochures.
	6.6 PUBLICATIONS
The NIH public access policy did not harm biomedical journals [PLOS Biology] We show here that implementation of the NIH policy was associated with slightly elevated mortality rates and mildly depressed natality rates of biomedical journals, but that birth rates so exceeded death rates that numbers of biomedical journals continued to rise, even in the face of the implementation of such a sweeping public access policy.
	6.7.1 IA/BIOINFORMATIQUE
Algorithm Identifies Cancer Patients in Need of Advance Care Planning Conversations [Penn Medicine] The researchers applied three different predictive models to 26,525 patients receiving outpatient oncology care at two hospitals within the University of Pennsylvania Health System. Each used information commonly available in patients’ electronic health records: demographic characteristics such as gender and age, standard comorbidity data such as whether a patient has high blood pressure, and laboratory and electrocardiogram data.